Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Pulse Biosciences, Inc.

< Previous 1 2 3 Next >
Pulse Biosciences Schedules Second Quarter 2023 Financial Results Conference Call for August 10, 2023
From Pulse Biosciences, Inc.
Via Business Wire
Tickers PLSE
Pulse Biosciences’ Nanosecond Pulsed Field Ablation (nsPFA™) Technology to be Featured in Several Presentations at The Heart Rhythm 2023 Annual Meeting
From Pulse Biosciences, Inc.
Via Business Wire
Tickers PLSE
Pulse Biosciences Reports Business Updates and First Quarter 2023 Financial Results
From Pulse Biosciences, Inc.
Via Business Wire
Tickers PLSE
Pulse Biosciences, Inc. Announces Planned Redemption of Warrants
From Pulse Biosciences, Inc.
Via Business Wire
Tickers PLSE
Pulse Biosciences, Inc. Appoints Dr. Gan Dunnington as Chief Medical Officer
From Pulse Biosciences, Inc.
Via Business Wire
Tickers PLSE
Pulse Biosciences Announces $65 Million Private Placement
From Pulse Biosciences, Inc.
Via Business Wire
Tickers PLSE
Pulse Biosciences Schedules First Quarter 2023 Financial Results Conference Call for May 11, 2023
From Pulse Biosciences, Inc.
Via Business Wire
Tickers PLSE
Pulse Biosciences Reports Fourth Quarter & Full Year 2022 Financial Results
From Pulse Biosciences, Inc.
Via Business Wire
Tickers PLSE
Pulse Biosciences Schedules Fourth Quarter & Full Year 2022 Financial Results Conference Call for March 30, 2023
From Pulse Biosciences, Inc.
Via Business Wire
Tickers PLSE
Pulse Biosciences Reports Third Quarter 2022 Financial Results
From Pulse Biosciences, Inc.
Via Business Wire
Tickers PLSE
Pulse Biosciences Schedules Third Quarter 2022 Financial Results Conference Call for November 10, 2022
From Pulse Biosciences, Inc.
Via Business Wire
Tickers PLSE
Pulse Biosciences Announces Positive Clinical Data on Nano-Pulse Stimulation Procedure for Low-Risk Basal Cell Carcinoma Lesions
From Pulse Biosciences, Inc.
Via Business Wire
Tickers PLSE
Pulse Biosciences Announces FDA 510(k) Clearance for the Treatment of Sebaceous Hyperplasia
From Pulse Biosciences, Inc.
Via Business Wire
Tickers PLSE
Pulse Biosciences Announces Strategic Change of Focus in Support of Significant Additional Opportunities for medicinal related Nano-Pulse Stimulation
From Pulse Biosciences, Inc.
Via Business Wire
Tickers PLSE
Pulse Biosciences Reports Second Quarter 2022 Financial Results
From Pulse Biosciences, Inc.
Via Business Wire
Tickers PLSE
Pulse Biosciences Receives FDA 510(k) Clearance of Expanded Energy Settings for use with the CellFX® System
From Pulse Biosciences, Inc.
Via Business Wire
Tickers PLSE
Pulse Biosciences Schedules Second Quarter 2022 Financial Results Conference Call for August 10, 2022
From Pulse Biosciences, Inc.
Via Business Wire
Tickers PLSE
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Pulse Biosciences, Inc.
Via Business Wire
Tickers PLSE
Pulse Biosciences, Inc. Announces the Closing of Its Rights Offering
From Pulse Biosciences, Inc.
Via Business Wire
Tickers PLSE
Pulse Biosciences, Inc. Announces Preliminary Results for its Rights Offering
From Pulse Biosciences, Inc.
Via Business Wire
Tickers PLSE
Pulse Biosciences Reports First Quarter 2022 Financial Results
From Pulse Biosciences, Inc.
Via Business Wire
Tickers PLSE
Pulse Biosciences, Inc. Announces Commencement of Rights Offering
From Pulse Biosciences, Inc.
Via Business Wire
Tickers PLSE
Pulse Biosciences Schedules First Quarter 2022 Financial Results Conference Call for May 11, 2022
From Pulse Biosciences, Inc.
Via Business Wire
Tickers PLSE
Pulse Biosciences to Present New Data on Nano-Pulse Stimulation Procedure for Sebaceous Hyperplasia and for Focal Epithelial Hyperplasia at 2022 American Society of Laser Medicine and Surgery Annual Conference
From Pulse Biosciences, Inc.
Via Business Wire
Tickers PLSE
Pulse Biosciences, Inc. Announces Rights Offering
From Pulse Biosciences, Inc.
Via Business Wire
Tickers PLSE
Pulse Biosciences Reports Fourth Quarter & Full Year 2021 Financial Results
From Pulse Biosciences, Inc.
Via Business Wire
Tickers PLSE
Pulse Biosciences Schedules Fourth Quarter and Full Year 2021 Financial Results Conference Call for March 31, 2022
From Pulse Biosciences, Inc.
Via Business Wire
Tickers PLSE
Pulse Biosciences Announces the Appointment of Kevin Danahy as Chief Commercial Officer
From Pulse Biosciences, Inc.
Via Business Wire
Tickers PLSE
Pulse Biosciences Provides an Update on Recent FDA 510(k) Submission
From Pulse Biosciences, Inc.
Via Business Wire
Tickers PLSE
Pulse Biosciences to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
From Pulse Biosciences, Inc.
Via Business Wire
Tickers PLSE
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.